The non-mevalonate pathway—also appearing as the mevalonate-independent pathway and the 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate (MEP/DOXP) pathway—is an alternative metabolic pathway for the biosynthesis of the isoprenoid precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP).[1][2][3] The currently preferred name for this pathway is the MEP pathway, since MEP is the first committed metabolite on the route to IPP.
Isoprenoid precursor biosynthesis
The mevalonate pathway (MVA pathway or HMG-CoA reductase pathway) and the MEP pathway are metabolic pathways for the biosynthesis of isoprenoid precursors: IPP and DMAPP. Whereas plants use both MVA and MEP pathway, most organisms only use one of the pathways for the biosynthesis of isoprenoid precursors. In plant cells IPP/DMAPP biosynthesis via the MEP pathway takes place in plastid organelles, while the biosynthesis via the MVA pathway takes place in the cytoplasm.[4] Most gram-negative bacteria, the photosynthetic cyanobacteria and green algae use only the MEP pathway.[5] Bacteria that use the MEP pathway include important pathogens such Mycobacterium tuberculosis.[6]
IPP and DMAPP serve as precursors for the biosynthesis of isoprenoid (terpenoid) molecules used in processes as diverse as protein prenylation, cell membrane maintenance, the synthesis of hormones, protein anchoring and N-glycosylation in all three domains of life.[citation needed] In photosynthetic organisms MEP-derived precursors are used for the biosynthesis of photosynthetic pigments, such as the carotenoids and the phytol chain of chlorophyll and light harvesting pigments.[5]
Bacteria such as Escherichia coli have been engineered for co-expressing biosynthesis genes of both the MEP and the MVA pathway.[7] Distribution of the metabolic fluxes between the MEP and the MVA pathway can be studied using 13C-glucose isotopomers.[8]
Non-mevalonate pathway reactions in the biosynthesis of isoprenoids. Redrawn verbatim from the scheme of Qidwai and coworkers [Fig. 2.].[9] Note, the enzyme abbreviations in this figure are non-standard (cf. Eisenreich et al.[10]), but are presented here and reproduced in the table to allow the two sets of data to be used together.
Reactions
The reactions of the MEP pathway are as follows, taken primarily from Eisenreich and co-workers, except where the bold labels are additional local abbreviations to assist in connecting the table to the scheme above:[10][9]
Dxs the first enzyme of the pathway is feedback inhibited by the products IPP and DMAPP. Dxs is active as a homo-dimer and the precise mechanism of enzyme inhibition has been debated in the field. It has been proposed that IPP/DMAPP are competing the co-factor TPP.[11] A more recent study suggested that IPP/DMAPP trigger monomerisation and subsequent degradation of the enzyme, via interaction with a monomer interaction site that differs from the active site of the enzyme.[12]
DXP reductoisomerase (also known as: DXR, DOXP reductoisomerase, IspC, MEP synthase), is a key enzyme in the MEP pathway. It can be inhibited by the natural productfosmidomycin, which is under study as a starting point to develop a candidate antibacterial or antimalarial drug.[13][14][15]
The intermediate, HMB-PP, is a natural activator of human Vγ9/Vδ2 T cells, the major γδ T cell population in peripheral blood, and cells that "play a crucial role in the immune response to microbial pathogens".[16]
IspH inhibitors: non-mevalonate Metabolic pathway that is essential for most bacteria but absent in humans, making it an ideal target for antibiotic development. This pathway, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, is responsible for biosynthesis of isoprenoids—molecules required for cell survival in most pathogenic bacteria and hence will be helpful in most usually antibacterial resistant bacteria.[17]
Metabolic engineering of the MEP/Non-mevalonate pathway
The MEP pathway has been extensively studied and engineered Escherichia coli, a commonly used microbial species for laboratory research and application.[18] IPP and DMAPP, the products of the MEP pathway can be used as substrates for the heterologous production of terpenoids with high value for application in the pharmaceutical and chemical industry. Upon expression of heterologous genes from different organisms, production of terpenoids like limonene, bisabolene and isoprene could be achieved in different microbial chassis.[19][20][21][22] Studies overexpressing different biosynthesis genes of the pathway revealed that expression of Dxs and Idi, catalyzing the first step and last step of the MEP pathway could significantly increase the yield of MEP derived terpenoids.[19][22] Dxs as the first enzyme of the pathway represents a bottleneck for the flux of carbon that enters the pathway. Idi which interconverts IPP to DMAPP and vice versa seems to be important for providing the respective substrate that is needed upon introduction of a heterologous carbon sink in engineered strains. A lot of metabolic engineering work on the MEP pathway has been done in cyanobacteria, photo-autotrophic microbes that can assimilate carbon dioxide from the atmosphere into various carbon containing metabolites, including terpenoids.[20][19][21] For biotechnology, cyanobacteria are, thus, an attractive platform for the sustainable production of high-value compounds.
References
^Rohmer M; Rohmer, Michel (1999). "The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants". Nat Prod Rep. 16 (5): 565–574. doi:10.1039/a709175c. PMID10584331.
^W. Eisenreich; A. Bacher; D. Arigoni; F. Rohdich (2004). "Review Biosynthesis of isoprenoids via the non-mevalonate pathway". Cellular and Molecular Life Sciences. 61 (12): 1401–1426. doi:10.1007/s00018-004-3381-z. PMID15197467. S2CID24558920.
^Lichtenthaler H (1999). "The 1-Deoxy-D-xylulose-5-phosphate pathway of isoprenoid biosynthesis in plants". Annual Review of Plant Physiology and Plant Molecular Biology. 50: 47–65. doi:10.1146/annurev.arplant.50.1.47. PMID15012203.
^Hale I, O'Neill PM, Berry NG, Odom A, Sharma R (2012). "The MEP pathway and the Development of Inhibitors as Potential Anti-Infective Agents". Med. Chem. Commun. 3 (4): 418–433. doi:10.1039/C2MD00298A.
^Jomaa H, Wiesner J, Sanderbrand S, et al. (1999). "Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs". Science. 285 (5433): 1573–6. doi:10.1126/science.285.5433.1573. PMID10477522.
^C. Zinglé; L. Kuntz; D. Tritsch; C. Grosdemange-Billiard; M. Rohmer (2010). "Isoprenoid Biosynthesis via the Methylerythritol Phosphate Pathway: Structural Variations around Phosphonate Anchor and Spacer of Fosmidomycin, a Potent Inhibitor of Deoxyxylulose Phosphate Reductoisomerase". J. Org. Chem.75 (10): 3203–3207. doi:10.1021/jo9024732. PMID20429517.
